Table. Baseline Characteristics.
| Characteristic | No. (%) | |
|---|---|---|
| All (n = 53 719) | Treated (n = 39 272) | |
| Sex | ||
| Female | 25 345 (47.2) | 18 526 (47.2) |
| Male | 28 374 (52.8) | 20 746 (52.8) |
| Age, mean (SD), y | 68.5 (9.3) | 67.9 (9.3) |
| Age at advanced NSCLC diagnosis | ||
| <55 y | 4436 (8.3) | 3527 (9.0) |
| 55-64 y | 12 452 (23.2) | 9658 (24.6) |
| 65-74 y | 19 050 (35.5) | 14 243 (36.3) |
| ≥75 y | 17 781 (33.1) | 11 844 (30.2) |
| Race and ethnicity | ||
| Asian | 1285 (2.4) | 1021 (2.6) |
| Black or African American | 4642 (8.6) | 3447 (8.8) |
| Hispanic or Latino | 1748 (3.3) | 1352 (3.4) |
| White | 36 316 (67.6) | 26 727 (68.1) |
| Othera | 4212 (7.8) | 3121 (7.9) |
| Missing | 5516 (10.3) | 3604 (9.2) |
| Stage at initial diagnosis | ||
| I | 2761 (5.1) | 1788 (4.6) |
| II | 2816 (5.2) | 1881 (4.8) |
| III | 11 145 (20.7) | 8544 (21.8) |
| IV | 33 253 (61.9) | 24 680 (62.8) |
| Unknown | 3744 (7.0) | 2379 (6.1) |
| Smoking status | ||
| History of smoking | ||
| Yes | 46 991 (87.5) | 34 055 (86.7) |
| No | 6146 (11.4) | 4895 (12.5) |
| Unknown | 582 (1.1) | 322 (0.8) |
| Geographic region | ||
| Northeast | 9636 (17.9) | 7200 (18.3) |
| South | 21 096 (39.3) | 15 676 (39.9) |
| Midwest | 7993 (14.9) | 5895 (15.0) |
| West | 8040 (15.0) | 6096 (15.5) |
| Missing | 6954 (12.9) | 4405 (11.2) |
| Insurance type | ||
| Medicare | 38 184 (71.1) | 27 034 (68.8) |
| Commercial | 5976 (11.1) | 4792 (12.2) |
| Other, including Medicaidb | 3085 (5.7) | 2382 (6.1) |
| Uninsured or unknown | 6474 (12.1) | 5064 (12.9) |
| Histological subtype | ||
| Squamous cell carcinoma | 13 938 (26.0) | 9991 (25.4) |
| Nonsquamous cell carcinomac | 36 881 (68.7) | 27 343 (69.6) |
| Not otherwise specified | 2900 (5.4) | 1938 (4.9) |
| First-line treatment regimen | ||
| No treatment | 14 447 (26.9) | 0 |
| Immune checkpoint | ||
| Inhibitor aloned | 4449 (8.3) | 4449 (11.3) |
| Inhibitor with chemotherapye | 4258 (7.9) | 4258 (10.8) |
| Tyrosine kinase inhibitorf | 4490 (8.4) | 4490 (11.4) |
| Other treatmentg | 26 075 (48.5) | 26 075 (66.4) |
Abbreviation: NSCLC, non–small cell lung cancer.
Other races and ethnicities include American Indian or Alaska Native, Hawaiian or Pacific Islander, and individuals of multiple races.
Other insurance types include Medicaid, other government program, other payer (unknown type), patient assistance program, and self-pay.
Examples include adenocarcinoma and large cell carcinoma.
Immune checkpoint inhibitors include pembrolizumab, nivolumab, atezolizumab, durvalumab, ipilimumab, and cemiplimab.
Also includes a small number of patients who received immune checkpoint inhibitors with tyrosine kinase inhibitors.
Tyrosine kinase inhibitors include osimertinib, erlotinib, afatinib, gefitinib, dacomitinib, mobocertinib, lazertinib, icotinib, sotarasib, adagrasib, alectinib, brigatinib, lorlatinib, ceritinib, crizotinib, entrectinib, dabrafenib, trametinib, vemurafenib, encorafenib, tepotinib, capmatinib, pralsetinib, selpercatinib, and larotrectinib.
Other treatments include chemotherapy including carboplatin, paclitaxel, and cisplatin.